Apeloa PharmaceuticalLtd Croissance future

Future contrôle des critères 1/6

Apeloa PharmaceuticalLtd devrait augmenter ses bénéfices et son chiffre d'affaires de 17.9% et de 11.1% par an respectivement. Le BPA devrait croître de de 17.7% par an. Le rendement des capitaux propres devrait être 17.5% dans 3 ans.

Informations clés

17.9%

Taux de croissance des bénéfices

17.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	19.5%
Taux de croissance des recettes	11.1%
Rendement futur des capitaux propres	17.5%
Couverture par les analystes	Good
Dernière mise à jour	04 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) Looks Inexpensive But Perhaps Not Attractive Enough

Nov 09

Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly

Sep 30

Lacklustre Performance Is Driving Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E

Aug 07

Is Apeloa PharmaceuticalLtd (SZSE:000739) Using Too Much Debt?

Jun 24

Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

May 08

Prévisions de croissance des bénéfices et des revenus

SZSE:000739 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	15,724	1,613	1,713	1,979	5
12/31/2025	14,344	1,366	1,459	1,742	6
12/31/2024	12,773	1,159	77	1,631	6
9/30/2024	12,264	1,074	764	1,349	N/A
6/30/2024	11,948	1,079	636	1,270	N/A
3/31/2024	11,587	1,060	454	1,089	N/A
12/31/2023	11,474	1,055	401	1,031	N/A
9/30/2023	11,494	1,183	784	1,304	N/A
6/30/2023	11,514	1,153	1,383	1,740	N/A
3/31/2023	11,529	1,076	899	1,377	N/A
1/1/2023	10,545	989	817	1,326	N/A
9/30/2022	10,094	851	326	822	N/A
6/30/2022	9,651	839	-140	617	N/A
3/31/2022	9,077	890	-160	635	N/A
1/1/2022	8,943	956	-90	612	N/A
9/30/2021	8,468	949	-35	722	N/A
6/30/2021	8,165	941	180	738	N/A
3/31/2021	8,146	879	675	1,048	N/A
12/31/2020	7,880	817	742	1,060	N/A
9/30/2020	7,606	752	1,156	1,276	N/A
6/30/2020	7,653	702	1,419	1,471	N/A
3/31/2020	7,236	598	1,282	1,340	N/A
12/31/2019	7,211	553	1,328	1,360	N/A
9/30/2019	7,122	529	1,258	1,316	N/A
6/30/2019	6,855	465	966	1,029	N/A
3/31/2019	6,605	414	714	811	N/A
12/31/2018	6,376	371	751	833	N/A
9/30/2018	6,246	367	433	523	N/A
6/30/2018	5,882	313	N/A	425	N/A
3/31/2018	5,674	275	N/A	410	N/A
12/31/2017	5,552	257	N/A	210	N/A
9/30/2017	5,313	253	N/A	465	N/A
6/30/2017	5,312	279	N/A	307	N/A
3/31/2017	5,112	274	N/A	304	N/A
12/31/2016	4,772	263	N/A	180	N/A
9/30/2016	4,476	201	N/A	223	N/A
6/30/2016	4,349	190	N/A	304	N/A
3/31/2016	4,284	198	N/A	255	N/A
12/31/2015	4,338	208	N/A	441	N/A
9/30/2015	4,195	231	N/A	580	N/A
6/30/2015	4,219	236	N/A	642	N/A
3/31/2015	4,281	241	N/A	750	N/A
12/31/2014	4,233	322	N/A	787	N/A
9/30/2014	4,112	313	N/A	435	N/A
6/30/2014	4,100	305	N/A	391	N/A
3/31/2014	3,991	274	N/A	198	N/A
12/31/2013	3,855	167	N/A	190	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 000739 ( 17.9% par an) est supérieure au taux d'épargne ( 2.8% ).

Bénéfices vs marché: Les bénéfices de 000739 ( 17.9% par an) devraient croître plus lentement que le marché CN ( 26.4% par an).

Croissance élevée des bénéfices: Les bénéfices de 000739 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 000739 ( 11.1% par an) devrait croître plus lentement que le marché de CN ( 14% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 000739 ( 11.1% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 000739 devrait être faible dans 3 ans ( 17.5 %).

Apeloa PharmaceuticalLtd Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 8.1% to CN¥21.56

Price target increased by 15% to CN¥28.46

Recent updates

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) Looks Inexpensive But Perhaps Not Attractive Enough

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023)

Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 18, 2024

Investor sentiment improves as stock rises 22%

Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in 2Q 2023)

Lacklustre Performance Is Driving Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Low P/E

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 16, 2024

Is Apeloa PharmaceuticalLtd (SZSE:000739) Using Too Much Debt?

Dividend increased to CN¥0.32

Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2023)

Apeloa Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 19, 2024

Price target decreased by 8.1% to CN¥21.56

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

New major risk - Earnings quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 17%

Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 3Q 2022)

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2023 Results on Aug 15, 2023

Apeloa Pharmaceutical Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 22 May 2023

Price target increased by 15% to CN¥28.46

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 2Q 2021)

Investor sentiment improved over the past week

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) announces an Equity Buyback for CNY 400 million worth of its shares.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Apeloa Pharmaceutical Co.,Ltd Proposes Final Dividend on A Shares for the Year 2021, Payable on 18 April 2022

Investor sentiment deteriorated over the past week

Apeloa Pharmaceutical Co.,Ltd Announces Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.23 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.13 in 1Q 2020)

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥0.69 (vs CN¥0.47 in FY 2019)

New 90-day high: CN¥25.52

Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day high: CN¥24.79

Third quarter earnings released

New 90-day low: CN¥22.50

Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 22, 2020

New 90-day high - CN¥27.14

Earnings released

New 90-day high - CN¥25.93

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 18, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance